VANCOUVER, June 15, 2016 /CNW/ - viDA Therapeutics, Inc. (viDA) announced today that Dr. Ron Nardi has been appointed to the Science Advisory Board (SAB).
Dr. Nardi currently serves as Chief Scientific Officer of Scioderm LLC, an Amicus Therapeutics company, focused on the development of an innovative topical treatment for Epidermolysis Bullosa. In September 2015, Scioderm, LLC, the first biotechnology company to ever receive Breakthrough Therapy Designation from the U.S. Food & Drug Administration, was acquired by Amicus Therapeutics of Cranbury, N.J., in a transaction valued at US$957 million.
Dr. Nardi brings more than 35 years of drug discovery, regulatory affairs and manufacturing as well as corporate management, including strategic direction assessments and integration of commercial research and development goals. Dr. Nardi previous roles included executive vice president of regulatory affairs and quality assurance at International Partnership for Microbicides, chief scientific officer for Ferring Pharmaceuticals A/S and later for BioValve Technologies, Inc. Dr. Nardi has been instrumental in obtaining regulatory approvals for a number of medical devices and novel therapeutics.
Dr. Nardi received his Ph.D. in pharmacology and toxicology from Rutgers University and completed a postdoctoral fellowship at the Institute for Cancer Research at Fox Chase Cancer Center.
"Dr. Nardi's experience and reputation will add significant value to the SAB as we begin our clinical development efforts," said Mr. Alistair Duncan, President & CEO.
viDA's SAB is comprised of renowned scientists, whose mission is to provide authoritative guidance with respect to both technological and commercial development. SAB members are Michael Abrams, PhD; Bruce McManus, MD, PhD, FRSC, FCAHS; Robert Young, PhD, FCIC, FRSC, MC; and, viDA's Scientific Founder and Chief Scientific Officer, David Granville, PhD, FAHA.
viDA Therapeutics, Inc. (viDA), a Vancouver, Canada based privately held biotechnology company, is focused on developing first-in-class therapies for treating autoimmune and chronic inflammatory diseases with high unmet need, including orphan products. The lead product candidate, VTI-1002, is in a topical formulation for the treatment of Discoid Lupus Erythematosus, an orphan chronic inflammatory autoimmune skin disorder. This disease is a severe chronic dermatological disease affecting women five times more than men. It can have a significant impact on quality of life due to severe facial disfigurement and scars. For additional information about viDA, please visit www.vidatherapeutics.com.
SOURCE viDA Therapeutics Inc
For further information: Media Contact: Alistair Duncan, B.Sc., C.P.A.- C.A. President & CEO, Phone: (604)762-4789, firstname.lastname@example.org